Furthermore, our previous report showed that leptin-induced upregulation of hepatic CD14 and the resulting hyper-reactivity to low-dose LPS during NASH progression were closely associated with increased liver inflammation [15]. Here, CD14 is linked to metabolic dysfunction-associated steatohepatitis.